InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $4.360 2.56 (142.22%)+
Announcement
Release
22 Oct 2025 8:31AM
Price at Release
$1.800
Full Release
download
Summary
4DMedical Limited, a leader in respiratory imaging technology, announced the commercial rollout of its CT:VQ™ technology at Stanford University, marking it as the first U.S. Academic Medical Centre to adopt the FDA-cleared technology. This milestone is part of 4DMedical's broader strategy to deploy CT:VQ™ across a network of key opinion leader sites in the U.S., aiming to set a new standard in cardiothoracic imaging by replacing traditional nuclear medicine VQ scans. The rollout allows Stanford to perform up to 20,000 CT scan analyses annually, facilitating reimbursement pathways and accelerating clinical adoption. Concurrently, 4DMedical, in partnership with AstraZeneca, expanded its Lung Health Screening Program in Brazil, adding five new hospitals to cover 38,000 CT scans annually, leveraging advanced imaging analytics to screen for lung cancer and other conditions.
Key Points
  • Stanford University first U.S. AMC to adopt CT:VQ™ commercially.
  • CT:VQ™ aims to replace nuclear medicine VQ scans with superior technology.
  • Up to 20,000 CT scans annually at Stanford under new agreement.
  • 4DMedical and AstraZeneca expand lung health program in Brazil.
  • Five new hospitals added to Brazilian screening program for 38,000 scans annually.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.